Picture of PolyPeptide AG logo

PPGN PolyPeptide AG News Story

0.000.00%
ch flag iconLast trade - 00:00
HealthcareSpeculativeMid CapHigh Flyer

Switzerland's PolyPeptide misses 2025 revenue estimates, expects margin improvement in 2026

Overview

Switzerland CDMO's 2025 revenue rose 15.6% but missed analyst expectations

EBITDA jumped 84% with margin up to 12%, driven by higher production and improved operations

Company expects 2026 revenue growth of 20-25% and further margin improvement

Outlook

PolyPeptide expects 2026 revenue to grow 20-25% versus 2025 at constant currency rates

Company sees 2026 EBITDA margin rising to mid- to high-teens

Capital expenditures in 2026 expected at 15-20% of revenue

Result Drivers

METABOLICS DEMAND - Co said strong demand for peptide-based therapeutics, especially in metabolics, drove revenue growth

CAPACITY EXPANSION - Successful ramp-up and utilization of new large-scale SPPS facility in Belgium contributed to higher production volumes

OPERATIONAL IMPROVEMENTS - Improved operational performance and product mix supported higher EBITDA margin

Company press release: ID:nEQ9DN61Qa

Key Details

MetricBeat/MissActualConsensus Estimate
FY RevenueMissEUR 389.33 mlnEUR 399.44 mln (6 Analysts)
FY CapexEUR 109.98 mln
FY Cash Flow from Operating ActivitiesEUR 77.51 mln
FY EBITEUR 8.69 mln
FY EBITDAEUR 46.76 mln
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell" The average consensus recommendation for the pharmaceuticals peer group is "buy" Wall Street's median 12-month price target for PolyPeptide Group AG is CHF38.00, about 55.1% above its March 11 closing price of CHF24.50 The stock recently traded at 63 times the next 12-month earnings vs. a P/E of 149 three months ago For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on PolyPeptide AG

See all news